Article ; Online: Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension.
The European respiratory journal
2013 Volume 41, Issue 4, Page(s) 872–878
Abstract: Vitamin K antagonists are advised in pulmonary arterial hypertension patients despite a lack of safety data. We reviewed major bleeding in three classes of pulmonary hypertension patients, all receiving vitamin K antagonists. Bleeding event rates were 5 ... ...
Abstract | Vitamin K antagonists are advised in pulmonary arterial hypertension patients despite a lack of safety data. We reviewed major bleeding in three classes of pulmonary hypertension patients, all receiving vitamin K antagonists. Bleeding event rates were 5.4 per 100 patient-years for patients with idiopathic pulmonary arterial hypertension, 19 per 100 patient-years for connective tissue disease related pulmonary arterial hypertension patients and 2.4 per 100 patient-years for chronic thromboembolic pulmonary hypertension patients. Life tables analysis showed that event-free survival was worse in patients with connective tissue disease related pulmonary hypertension than in patients with idiopathic pulmonary arterial hypertension (Wilcoxon=12.8; p<0.001), and patients with chronic thromboembolic pulmonary hypertension (Wilcoxon=23.2; p<0.001). Patients with idiopathic pulmonary arterial hypertension suffered more events than patients with chronic thromboembolic pulmonary hypertension (Wilcoxon=7.2; p<0.01). Major bleeding was independent of age, sex, target international normalised ratio (INR) range, documented INR, vitamin K antagonist type, or right atrial pressure, but was associated with use of prostacyclin analogues. Major bleeding risk during vitamin K antagonist therapy differs among groups of patients with pulmonary hypertension. Further research regarding optimal anticoagulant therapy is needed, as well as risk-benefit analyses for pulmonary hypertension patients with a higher bleeding propensity. |
---|---|
MeSH term(s) | Administration, Oral ; Adult ; Aged ; Anticoagulants/adverse effects ; Disease-Free Survival ; Female ; Fibrinolytic Agents/therapeutic use ; Hemorrhage/chemically induced ; Humans ; Hypertension, Pulmonary/complications ; Hypertension, Pulmonary/drug therapy ; International Normalized Ratio ; Male ; Middle Aged ; Platelet Count ; Retrospective Studies ; Vitamin K/antagonists & inhibitors |
Chemical Substances | Anticoagulants ; Fibrinolytic Agents ; Vitamin K (12001-79-5) |
Language | English |
Publishing date | 2013-04 |
Publishing country | England |
Document type | Journal Article |
ZDB-ID | 639359-7 |
ISSN | 1399-3003 ; 0903-1936 |
ISSN (online) | 1399-3003 |
ISSN | 0903-1936 |
DOI | 10.1183/09031936.00039212 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 2322: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MO 292: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.